Selected article for: "activity modulation and low concentration"

Title: 2015 ACVIM Forum Research Abstract Program
  • Document date: 2015_5_27
  • ID: 3pnuj5ru_264
    Snippet: Conclusions: Minoxidil has activity against pulmonary metastasis ex vivo, but at significantly higher doses than are biologically achievable. Investigation of the in vivo effects of minoxidil on osteosarcoma metastasis in mice is planned; intratumoral drug levels will be measured to determine whether minoxidil concentration in tissues can explain the discrepancy between low plasma levels achieved and the high exposures required for anti-metastati.....
    Document: Conclusions: Minoxidil has activity against pulmonary metastasis ex vivo, but at significantly higher doses than are biologically achievable. Investigation of the in vivo effects of minoxidil on osteosarcoma metastasis in mice is planned; intratumoral drug levels will be measured to determine whether minoxidil concentration in tissues can explain the discrepancy between low plasma levels achieved and the high exposures required for anti-metastatic activity and PLOD2 modulation. Feline acromegaly is an increasingly recognised endocrinopathy, caused by chronic excessive serum growth hormone concentration produced by a functional somatotrophinoma in the pars distalis of the anterior pituitary gland. The underlying pathogenesis for the development of most human somatotrophinomas is poorly understood. The majority of human somatotrophinomas are sporadic, however up to 20% of familial isolated pituitary adenomas are caused by germline mutations of the aryl-hydrocarbon-receptor interacting protein (AIP). Feline acromegaly has phenotypic and biochemical similarities to human families with AIP mutations, such as male predominance, somatotroph macroadenoma and resistance to octreotide therapy.

    Search related documents:
    Co phrase search for related documents
    • achieve plasma level and plasma level: 1
    • AIP mutation and aryl hydrocarbon receptor: 1, 2
    • AIP mutation and hydrocarbon receptor: 1, 2
    • anterior pituitary gland and aryl hydrocarbon receptor: 1
    • anterior pituitary gland and feline acromegaly: 1
    • anterior pituitary gland and functional somatotrophinoma: 1
    • anterior pituitary gland and human somatotrophinomas: 1
    • anterior pituitary gland and human somatotrophinomas majority: 1
    • anterior pituitary gland and hydrocarbon receptor: 1
    • anterior pituitary gland and male predominance: 1
    • anterior pituitary gland and octreotide therapy: 1
    • anterior pituitary gland and pituitary gland: 1, 2, 3, 4, 5, 6, 7, 8
    • anterior pituitary gland and resistance somatotroph macroadenoma male predominance: 1
    • anterior pituitary gland and significantly high dose: 1, 2